Promising One-Year Efficacy Results: AlloStem™ for Diabetes

Exciting Developments in Type 2 Diabetes Treatment

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a leading clinical-stage biotechnology company specializing in innovative regenerative medicine solutions, recently revealed encouraging one-year follow-up findings from their AlloStem™ (CELZ-201) Type 2 Diabetes pilot study aimed at late-stage patients. CELZ-201, an off-the-shelf and proprietary allogenic cell line, presents a breakthrough in diabetes care.

Groundbreaking Clinical Study Results

The pilot study involved 20 patients, distinguishing between those who received CELZ-201 and those who underwent optimized medical therapy. Impressively, CELZ-201 showed an 80% efficacy rate in diminishing insulin dependency and stabilizing hemoglobin A1c levels without any reported serious adverse effects. These findings affirm the safety and potential benefits of CELZ-201 as a transformative option for managing late-stage Type 2 Diabetes.

Significance of the Findings

This study’s outcomes are crucial for patients struggling with late-stage Type 2 Diabetes, a condition that affects millions. Creative Medical Technology's findings lend further credibility to the safety and effectiveness of their procedure, which aligns with protocols utilized in their FDA-approved Type 1 Diabetes clinical trial.

Future Directions for AlloStem™

The encouraging results propel Creative Medical Technology toward advancing the AlloStem (CELZ-201) treatment and exploring diverse applications for this innovative therapy to broaden their product pipeline. Timothy Warbington, the President and CEO, emphasized the importance of these findings in furthering their commitment to reshaping diabetes treatment and enhancing the quality of life for patients who may not benefit from traditional autologous therapies.

Type 2 Diabetes: A Growing Concern

Today, Type 2 diabetes affects a staggering 90-95% of the 38 million individuals diagnosed with diabetes in the U.S. Initially treated with lifestyle changes and medications, many eventually transition to insulin therapy as the disease progresses. Alarmingly, diabetes remains the eighth leading cause of death in the nation, affecting over 96 million adults classified as prediabetic, with a significant majority unaware of their health conditions.

Company Profile: Creative Medical Technology Holdings, Inc.

Creative Medical Technology stands at the forefront of biotechnology, committed to developing revolutionary regenerative cell therapies. Their diverse pipeline showcases a broad focus on endocrinology, immunotherapy, and treatment alternatives for orthopedic and neurological disorders. For further information about their innovative solutions, please visit www.creativemedicaltechnology.com.

Frequently Asked Questions

What is CELZ-201?

CELZ-201 is an allogenic cell line developed to treat late-stage Type 2 Diabetes, designed to reduce dependency on insulin and stabilize blood sugar levels.

What were the key findings of the study?

The study demonstrated an 80% overall efficacy in reducing insulin dependency and stabilizing hemoglobin A1c levels, with no serious adverse effects reported.

What does the future hold for AlloStem™?

Creative Medical Technology plans to further develop AlloStem (CELZ-201) and explore additional applications to enhance their treatment pipeline.

Who can benefit from the AlloStem™ treatment?

Patients with late-stage Type 2 Diabetes, especially those who have not responded well to traditional therapies, can potentially benefit from this innovative treatment.

How does Creative Medical Technology impact diabetes care?

Through pioneering research and development, Creative Medical Technology aims to transform diabetes treatment, providing more effective solutions for managing this widespread condition.

About The Author

Hello Kelly Martin here, a financial and publicly traded company specialist committed to writing with clarity and sage advice. Having a wealth of experience and a thorough grasp of corporate dynamics and the financial environment, my main goal in writing blog posts and articles is to provide insightful analysis together with useful guidance. My objective is to arm readers with the information they need to comprehend the complexities of publicly traded companies and make wise financial decisions.

Writing for several financial blogs has let me interact with a wide range of readers, from novice investors to seasoned pros looking for fresh perspectives. My goal is to make corporate analysis and finance understandable and interesting so you may confidently negotiate the intricacies of the financial world. I appreciate you traveling with me toward success and financial literacy.

Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.